IPHA
Innate Pharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 0
stock price surged significantly
consensus rating "Strong Buy"
Upward Gap
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About IPHA
Innate Pharma S.A.
A company that developing therapeutic antibodies designed to harness the immune system to treat cancer
Biological Technology
09/23/1999
10/17/2019
NASDAQ Stock Exchange
179
12-31
Depository Receipts (Ordinary Shares)
117 Avenue de Luminy, 13009 Marseille, France
--
Founded on September 23, 1999, Innate Pharma S.A. is a biotechnology company dedicated to the discovery, development and commercialization of first-in-class therapeutic antibodies designed to harness the immune system for the treatment of tumor indications with serious unmet medical needs. The company has extensive experience in the research and development of immuno-oncology and is a pioneer in understanding natural killer cell or NK cell biology.
Company Financials
EPS
IPHA has released its 2022 Q2 earnings. EPS was reported at 0.09, versus the expected 0.00, beating expectations. The chart below visualizes how IPHA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available